Nivolumab, Cabozantinib S-Malate and Ipilimumab in Treating Patients with Recurrent Stage IV Non-small Cell Lung Cancer

Skip to Content

Clinical Trial Details

Nivolumab, Cabozantinib S-Malate & Ipilimumab in Recurrent Stage IV Non-small Cell Lung Cancer Pts.

Nivolumab, Cabozantinib S-Malate and Ipilimumab in Treating Patients with Recurrent Stage IV Non-small Cell Lung Cancer

Objective

Visit the National Cancer Institute's Web Site.

This partially randomized phase II trial studies how well nivolumab, cabozantinib s-malate, and ipilimumab work in treating patients with stage IV non-small cell lung cancer that has come back. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab, cabozantinib s-malate, and ipilimumab may work better in treating patient with stage IV non-small cell lung cancer.

(NCT# 03468985)

IRB Protocol Number
ECOG-ACRIN EA5152

Clinical Trial Categories

  • Lung Cancer
Contact
NH Oncology Hematology Clinical Research Dept. at 603-224-2556

Location

  • Concord Hospital
    250 Pleasant Street
    Concord, NH 03110
    Main: 603-225-2711
    Alternate: 800-327-0464